BCX-34 data

BCRX reported preliminary results from a double-blind, placebo-controlled Phase II trial of BCX-34 in 90 psoriasis patients. Patients were treated for three months with a topical cream containing 1 percent drug. End points were reductions in erythema, scaling and thickness of plaques, which were combined for a total score, and a global physician assessment.

The trial was conducted at two sites in northern climates and two sunbelt sites. BCRX said that combined data from all four sites didn't show a significant difference between drug and placebo. However, there was a statistically significant difference between treated and placebo patients on both end points at the northern sites. ...